GlassScriptPhysician profile
Dawn Rose Hinkle
NPI 1174887368
$2,500.99
in general payments reported to CMS, 2019-2025
25 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $735 · 2023: $509 · 2024: $365 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,063.82 | 2021-2025 | |
| Eisai INC. | $233.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $180.77 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $129.62 | 2023 | Jornay Pm |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.74 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $83.45 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $78.54 | 2021 | |
| Pfizer INC. | $72.36 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $53.64 | 2022-2023 | Qelbree |
| Endo Pharmaceuticals INC. | $39.27 | 2022-2023 | Nascobal |
| Lundbeck LLC | $38.41 | 2022-2024 | Rexulti |
| Gilead Sciences, INC. | $37.06 | 2021 | |
| Exact Sciences Corporation | $33.33 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.52 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.83 | 2021-2022 | |
| Almatica Pharma LLC | $27.62 | 2024-2025 | Teriparatide, Loreev Xr |
| Alkermes, INC. | $21.49 | 2025 | Aristada, Lybalvi |
| Ibsa Pharma INC. | $20.97 | 2021 | |
| Therapeuticsmd, INC. | $17.33 | 2021 | |
| Merck Sharp & Dohme LLC | $16.13 | 2022 | |
| Impel Pharmaceuticals INC. | $15.87 | 2023 | Trudhesa |
| Radius Health, INC. | $14.68 | 2021 | |
| Alvogen INC | $14.47 | 2024 | Teriparatide |
| Alfasigma USA, INC. | $14.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Hinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.